{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T16:52:35Z","timestamp":1781628755101,"version":"3.54.5"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Nucl Med"],"published-print":{"date-parts":[[2026,5]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>\n                      Lutetium (\u00b9\u2077\u2077Lu) oxodotreotide (\u00b9\u2077\u2077Lu-DOTATATE, Lutathera\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) is widely used for neuroendocrine tumors. Although cardiovascular adverse events are not well recognized, we frequently observe bradycardia during infusion under monitoring. We aimed to characterize heart-rate changes during \u00b9\u2077\u2077Lu-DOTATATE administration and explore risk factors for bradycardia.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed 130 administrations in 37 patients (April 2022\u2013April 2025). Heart rate was recorded at four time points: (i) upon entering the room, (ii) the start of \u00b9\u2077\u2077Lu-DOTATATE administration (during L-lysine\/L-arginine amino acid infusion), (iii) dose-rate adjustment at 10\u00a0min, and (iv) the end of infusion at 30\u00a0min. Repeated-measures ANOVA was used to evaluate changes in vital signs. Demographics, comorbidities, and laboratory values (electrolytes, hemoglobin, albumin, total protein) were collected. Cardiomegaly on imaging was determined visually using recent CT or MRI. Multivariable analyses were performed to examine predictors of heart rate change. Patient characteristics were also compared between those with and without bradycardia (\u2264\u200950\u00a0bpm) using the chi-squared test.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean heart rate decreased over time: upon entering the room (72.3\u00a0bpm), at the start of \u00b9\u2077\u2077Lu-DOTATATE administration (64.5\u00a0bpm), and during dose rate adjustment (59.5\u00a0bpm). (all\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&lt;\u20090.001). Furthermore, at the end of infusion (66.2\u00a0bpm), it returned to a level similar to that at the start of \u00b9\u2077\u2077Lu-DOTATATE administration; patterns were similar across treatment cycles. Mean blood pressure decreased upon initiation of \u00b9\u2077\u2077Lu-DOTATATE (119.3\/73.6 mmHg) compared to upon entering the room (127.8\/78.3 mmHg), with no differences observed at other time points. Twenty-two administrations reached\u2009\u2264\u200950\u00a0bpm; chest discomfort occurred in five instances and resolved with observation. Multivariable models showed no significant predictors for the magnitude of heart-rate change. However, cardiac enlargement was associated with bradycardia during rate adjustment (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.045). No significant associations were seen with age, sex, history of arrhythmia, or laboratory parameters.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Transient heart-rate decline, occasionally meeting bradycardia, commonly occurs during \u00b9\u2077\u2077Lu-DOTATATE infusion but typically resolves by completion and rarely requires intervention. Recognizing its benign, self-limiting nature\u2014and the higher susceptibility among patients with preexisting cardiac enlargement\u2014may reduce unnecessary treatment interruptions and improve procedural safety.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s12149-025-02150-4","type":"journal-article","created":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T11:33:39Z","timestamp":1767008019000},"page":"496-506","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Transient bradycardia during 177Lu-DOTATATE therapy: A clinically manageable phenomenon with increased risk in patients with cardiac enlargement"],"prefix":"10.1007","volume":"40","author":[{"given":"Hirofumi","family":"Yamada","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5151-3146","authenticated-orcid":false,"given":"Kota","family":"Yokoyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Tsuchiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miki","family":"Miura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eriko","family":"Katsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiichi","family":"Akahoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomomi","family":"Akiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Takino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daisuke","family":"Ban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ukihide","family":"Tateishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,29]]},"reference":[{"issue":"2","key":"2150_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1056\/NEJMoa1607427","volume":"376","author":"J Strosberg","year":"2017","unstructured":"Strosberg J, El-Haddad G, Wolin E, Hendifar A, Yao J, Chasen B, et al. Phase 3 trial of (177)Lu-Dotatate for midgut neuroendocrine tumors. N Engl J Med. 2017;376(2):125\u201335.","journal-title":"N Engl J Med"},{"issue":"9","key":"2150_CR2","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.2967\/jnumed.124.267497","volume":"65","author":"A Al-Ibraheem","year":"2024","unstructured":"Al-Ibraheem A, Abdlkadir A, Al-Adhami D, Herrmann K. [(177)Lu]Lu-DOTATATE may resensitize neuroendocrine tumors to hormonal therapy: initial clinical experience in renal carcinoid. J Nucl Med. 2024;65(9):1494.","journal-title":"J Nucl Med"},{"issue":"5","key":"2150_CR3","doi-asserted-by":"publisher","first-page":"746","DOI":"10.2967\/jnumed.123.265703","volume":"65","author":"ES Delpassand","year":"2024","unstructured":"Delpassand ES, Yazdi SM, Ghantoji S, Nakasato A, Strickland C, Nunez R, et al. Effectiveness and safety of retreatment with (177) Lu-Dotatate in patients with progressive neuroendocrine tumors: a retrospective real-world study in the United States. J Nucl Med. 2024;65(5):746\u201352.","journal-title":"J Nucl Med"},{"key":"2150_CR4","unstructured":"U.S. Food and Drug Administration. LUTATHERA\u00ae (lutetium Lu 177 dotatate) injection: for intravenous use, highlights of prescribing information ; 2018 (revised 2024).NDA 208700\/S-032 ed. Silver Spring (MD); 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/208700s032lbl"},{"key":"2150_CR6","unstructured":"Kl\u00f6ppel G, Adsay NV, Couvelard A, et al. Pancreatic neuroendocrine neoplasms: Introduction. In: WHO Classification of Tumours Editorial Board. Digestive system tumours. Lyon (France): International Agency for Research on Cancer; 2019. p. 343-346. https:\/\/publications.iarc.fr\/579"},{"key":"2150_CR7","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.anndiagpath.2017.04.005","volume":"29","author":"JY Kim","year":"2017","unstructured":"Kim JY, Hong S-M, Ro JY. Recent updates on grading and classification of neuroendocrine tumors. Ann Diagn Pathol. 2017;29:11\u20136.","journal-title":"Ann Diagn Pathol"},{"issue":"Suppl 2","key":"2150_CR8","first-page":"S219","volume":"31","author":"EP Krenning","year":"1999","unstructured":"Krenning EP, Valkema R, Kooij PP, Breeman WA, Bakker WH, deHerder WW, et al. Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide. Ital J Gastroenterol Hepatol. 1999;31(Suppl 2):S219\u201323.","journal-title":"Ital J Gastroenterol Hepatol"},{"issue":"3","key":"2150_CR9","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y. Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transpl. 2013;48(3):452\u20138.","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2150_CR10","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1002\/clc.4960230314","volume":"23","author":"EA Bocchi","year":"2000","unstructured":"Bocchi EA, De Moraes AV, Esteves-Filho A, Bacal F, Auler JO, Carmona MJ, et al. L\u2010Arginine reduces heart rate and improves hemodynamics in severe congestive heart failure. Clin Cardiol. 2000;23(3):205\u201310.","journal-title":"Clin Cardiol"},{"issue":"5","key":"2150_CR11","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1046\/j.1365-2125.1998.00803.x","volume":"46","author":"SM Bode-B\u00f6ger","year":"1998","unstructured":"Bode-B\u00f6ger SM, B\u00f6ger RH, Galland A, Tsikas D, Fr\u00f6lich JC. L\u2010arginine\u2010induced vasodilation in healthy humans:pharmacokinetic\u2013pharmacodynamic relationship. Br J Clin Pharmacol. 1998;46(5):489\u201397.","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"2150_CR12","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1161\/hy0102.098308","volume":"39","author":"S Chowdhary","year":"2002","unstructured":"Chowdhary S, Nuttall SL, Coote JH, Townend JN. l-Arginine augments cardiac vagal control in healthy human subjects. Hypertension. 2002;39(1):51\u20136.","journal-title":"Hypertension"},{"issue":"4","key":"2150_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/S0008-6363(00)00267-4","volume":"49","author":"A Mendes Ribeiro","year":"2001","unstructured":"Mendes Ribeiro A. Abnormalities in\u202f?-arginine transport and nitric oxide biosynthesis in chronic renal and heart failure. Cardiovasc Res. 2001;49(4):697\u2013712.","journal-title":"Cardiovasc Res"},{"issue":"4","key":"2150_CR14","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1136\/rapm-00115550-200807000-00008","volume":"33","author":"R Owczuk","year":"2008","unstructured":"Owczuk R, Wenski W, Polak-Krzeminska A, Twardowski P, Arszu\u0142owicz R, Dylczyk-Sommer A, et al. Ondansetron given intravenously attenuates arterial blood pressure drop due to spinal anesthesia: a double-blind, placebo-controlled study. Reg Anesth Pain Med. 2008;33(4):332\u20139.","journal-title":"Reg Anesth Pain Med"},{"issue":"3","key":"2150_CR15","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/BF00283745","volume":"22","author":"W Wieling","year":"1982","unstructured":"Wieling W, van Brederode JF, de Rijk LG, Borst C, Dunning AJ. Reflex control of heart rate in normal subjects in relation to age: a data base for cardiac vagal neuropathy. Diabetologia. 1982;22(3):163\u20136.","journal-title":"Diabetologia"},{"issue":"2","key":"2150_CR16","doi-asserted-by":"publisher","first-page":"394","DOI":"10.2307\/3576382","volume":"99","author":"WA Alter","year":"1984","unstructured":"Alter WA 3rd, Catravas GN, Hawkins RN, Lake CR. Effect of ionizing radiation on physiological function in the anesthetized rat. Radiat Res. 1984;99(2):394\u2013409.","journal-title":"Radiat Res"},{"key":"2150_CR17","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/3579143","volume":"2020","author":"Z Ping","year":"2020","unstructured":"Ping Z, Peng Y, Lang H, Xinyong C, Zhiyi Z, Xiaocheng W, et al. Oxidative stress in radiation-induced cardiotoxicity. Oxid Med Cell Longev. 2020;2020:3579143.","journal-title":"Oxid Med Cell Longev"},{"key":"2150_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.envint.2020.106235","volume":"146","author":"S Tapio","year":"2021","unstructured":"Tapio S, Little MP, Kaiser JC, Impens N, Hamada N, Georgakilas AG, et al. Ionizing radiation-induced circulatory and metabolic diseases. Environ Int. 2021;146:106235.","journal-title":"Environ Int"},{"key":"2150_CR19","doi-asserted-by":"publisher","first-page":"e072924","DOI":"10.1136\/bmj-2022-072924","volume":"380","author":"MP Little","year":"2023","unstructured":"Little MP, Azizova TV, Richardson DB, Tapio S, Bernier MO, Kreuzer M, et al. Ionising radiation and cardiovascular disease: systematic review and meta-analysis. BMJ. 2023;380:e072924.","journal-title":"BMJ"},{"issue":"8","key":"2150_CR20","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1097\/RLU.0000000000005861","volume":"50","author":"H Chen","year":"2025","unstructured":"Chen H, Ma J. Post-marketing safety evaluation of lutathera (177Lu-DOTATATE): a pharmacovigilance analysis of FDA adverse event reporting system. Clin Nucl Med. 2025;50(8):714\u201320.","journal-title":"Clin Nucl Med"},{"issue":"4","key":"2150_CR21","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/0031-9384(94)90058-2","volume":"55","author":"C Cajochen","year":"1994","unstructured":"Cajochen C, Pischke J, Aeschbach D, Borb\u00e9ly AA. Heart rate dynamics during human sleep. Physiol Behav. 1994;55(4):769\u201374.","journal-title":"Physiol Behav"},{"issue":"7","key":"2150_CR22","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1007\/s12149-025-02050-7","volume":"39","author":"M Hotta","year":"2025","unstructured":"Hotta M, Horikawa D, Kurihara K, Ohashi S, Saito K, Inagaki F. Pre-treatment 111In-pentetreotide SPECT\/CT vs. baseline 177Lu-DOTATATE SPECT\/CT: are there differences in lesion uptake and detectability? Ann Nucl Med. 2025;39(7):747\u201353.","journal-title":"Ann Nucl Med"},{"issue":"9","key":"2150_CR23","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.2967\/jnumed.118.223016","volume":"60","author":"TA Hope","year":"2019","unstructured":"Hope TA, Calais J, Zhang L, Dieckmann W, Millo C. (111)In-pentetreotide scintigraphy versus (68)Ga-DOTATATE PET: impact on Krenning scores and effect of tumor burden. J Nucl Med. 2019;60(9):1266\u20139.","journal-title":"J Nucl Med"}],"container-title":["Annals of Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12149-025-02150-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12149-025-02150-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T15:54:11Z","timestamp":1781625251000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12149-025-02150-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,29]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["2150"],"URL":"https:\/\/doi.org\/10.1007\/s12149-025-02150-4","relation":{},"ISSN":["0914-7187","1864-6433"],"issn-type":[{"value":"0914-7187","type":"print"},{"value":"1864-6433","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,29]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki (1964) and was approved by the Ethics Review Committee of Institute of Science Tokyo (Approval No. I2025-076).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"This retrospective study was approved by the institutional ethics committee of the Institute of Science Tokyo (No. I2025-076) and conducted in accordance with the 1964 Declaration of Helsinki. Informed consent was obtained using an opt-out method.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained using an opt-out method approved by the institutional ethics committee.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}}]}}